AU2004202980B2 - Methods for assessing and treating leukemia - Google Patents

Methods for assessing and treating leukemia Download PDF

Info

Publication number
AU2004202980B2
AU2004202980B2 AU2004202980A AU2004202980A AU2004202980B2 AU 2004202980 B2 AU2004202980 B2 AU 2004202980B2 AU 2004202980 A AU2004202980 A AU 2004202980A AU 2004202980 A AU2004202980 A AU 2004202980A AU 2004202980 B2 AU2004202980 B2 AU 2004202980B2
Authority
AU
Australia
Prior art keywords
fti
patient
gene
treatment
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004202980A
Other languages
English (en)
Other versions
AU2004202980A1 (en
Inventor
Mitch Raponi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Diagnostics LLC
Original Assignee
Veridex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex LLC filed Critical Veridex LLC
Publication of AU2004202980A1 publication Critical patent/AU2004202980A1/en
Priority to AU2005201935A priority Critical patent/AU2005201935B2/en
Application granted granted Critical
Publication of AU2004202980B2 publication Critical patent/AU2004202980B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2004202980A 2003-07-01 2004-06-30 Methods for assessing and treating leukemia Ceased AU2004202980B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2005201935A AU2005201935B2 (en) 2004-05-06 2005-05-06 Prognostic for hematological malignancy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61144603A 2003-07-01 2003-07-01
US10/611,446 2003-07-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2005201935A Addition AU2005201935B2 (en) 2004-05-06 2005-05-06 Prognostic for hematological malignancy

Publications (2)

Publication Number Publication Date
AU2004202980A1 AU2004202980A1 (en) 2005-01-20
AU2004202980B2 true AU2004202980B2 (en) 2009-05-07

Family

ID=33541317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004202980A Ceased AU2004202980B2 (en) 2003-07-01 2004-06-30 Methods for assessing and treating leukemia

Country Status (9)

Country Link
EP (1) EP1502962A3 (OSRAM)
JP (1) JP2005034151A (OSRAM)
KR (1) KR20050004076A (OSRAM)
CN (1) CN1626679A (OSRAM)
AR (1) AR044984A1 (OSRAM)
AU (1) AU2004202980B2 (OSRAM)
BR (1) BRPI0403291A (OSRAM)
CA (1) CA2472846A1 (OSRAM)
MX (1) MXPA04006494A (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050003422A1 (en) * 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
AR048945A1 (es) * 2004-05-06 2006-06-14 Veridex Llc Pronostico para leucemia mieloide cronica
WO2006124836A1 (en) * 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
US20110009387A1 (en) * 2007-06-12 2011-01-13 Andrea Dawn Basso-Porcaro Histone h2ax (hh2ax) biomarker for fti sensitivity
CN104204222A (zh) * 2011-08-30 2014-12-10 Dcb-美国有限责任公司 预测易罹患卵巢赘瘤或卵巢癌预后的生物标记
CN109628591B (zh) * 2018-12-04 2022-04-15 南方医科大学南方医院 用于肺腺癌预后预测的标志物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003038129A2 (en) * 2001-10-30 2003-05-08 Ortho-Clinical Diagnostics, Inc. Methods for assessing and treating leukemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003038129A2 (en) * 2001-10-30 2003-05-08 Ortho-Clinical Diagnostics, Inc. Methods for assessing and treating leukemia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Rowinsky EK et al, Journal of Clinical Oncology, Vol 17, 1999, pages 3631-3652 *

Also Published As

Publication number Publication date
CA2472846A1 (en) 2005-01-01
CN1626679A (zh) 2005-06-15
AU2004202980A1 (en) 2005-01-20
KR20050004076A (ko) 2005-01-12
AR044984A1 (es) 2005-10-12
EP1502962A2 (en) 2005-02-02
EP1502962A3 (en) 2006-01-11
MXPA04006494A (es) 2005-04-19
JP2005034151A (ja) 2005-02-10
BRPI0403291A (pt) 2005-07-12

Similar Documents

Publication Publication Date Title
Park et al. Molecular testing of brain tumor
EP3198026B1 (en) Method of determining pik3ca mutational status in a sample
Guarini et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression
EP1824997B1 (en) Genetic alteration useful for the response prediction of malignant neoplasia to taxane-based medical treatment
US20120177641A1 (en) Gefitnib Sensitivity-Related Gene Expression and Products and Methods Related Thereto
AU2013232379A1 (en) Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia
JP2011512785A (ja) ファルネシルトランスフェラーゼ治療に対する急性骨髄性白血病応答を決定する方法
EP1611890B1 (en) Methods for assessing and treating cancer
CA2755260C (en) Method for determining sensitivity to irinotecan and use thereof
US8216783B2 (en) Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors
CN105765081A (zh) 一种用于预测对采用egfr抑制剂的治疗的响应性的方法
AU2005201935B2 (en) Prognostic for hematological malignancy
US7932036B1 (en) Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2006066240A2 (en) Methods for assessing patients with acute myeloid leukemia
JP2022530390A (ja) 抗精神病剤の応答を予測するための方法
EP1502962A2 (en) Methods for assessing and treating cancer
US20120095030A1 (en) Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
WO2015085164A2 (en) Uveal melanoma prognosis
MX2014006186A (es) Capacidad de respuesta a los inhibidores de la angiogenesis.
WO2012139945A1 (en) Method for predicting survival in cancer patients
WO2026050734A1 (en) Method of treating and diagnosing cancers
AU2012202170A1 (en) Prognostic for hematological malignancy
AU2014213541B2 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
HK1241934A1 (en) Method of determining pik3ca mutational status in a sample
HK1241934B (en) Method of determining pik3ca mutational status in a sample

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 23, NO 17, PAGE(S) 7982 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX DELETE ALL REFERENCE TO 2004202980.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired